The purpose of this registry is to record information on therapy reality of malignant lymphatic systemic diseases by office-based haematologists in Germany.
The TLN is a prospective, longitudinal, nation wide cohort study with the purpose to record information on the antineoplastic treatment of lymphatic neoplasms in Germany. The registry will follow patients for up to five years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. The impact of nutrition (LyNut) and physical activity (LyNut) on the course of the adjuvant disease will be examined in patients with indolent and aggressive Non-Hodgin Lymphoma, as well as long-term effects of systemic treatment (LyTox) and quality of life (LyLife) in patients with multiple myeloma.
Study Type
OBSERVATIONAL
Enrollment
3,795
Course of treatment (treatment reality)
Documentation of anamnestic data and therapy sequences
Time frame: 5 years per patient
Effectiveness of treatment
Documentation of response rates and progression-free survival per therapy sequence, overall survival time and adverse reactions
Time frame: 5 years per patient
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.